Pharmaceuticals

Cresco Labs Inc.

Cresco Labs Inc. released FY2026 Q1 earnings on May 8 Pre-Market EST, actual revenue USD 151.33 M (forecast USD 148.72 M), actual EPS USD -0.0399

Cresco Labs Inc. to Release FY2026 Q1 Earnings on May 8 Pre-Market EST, Forecast Revenue USD 148.88 M

Cresco Labs CEO Praises DOJ's Rescheduling of Medical Marijuana

Cresco Labs Inc. released FY2025 Q4 earnings on March 5 Pre-Market EST, actual revenue USD 161.55 M (forecast USD 161.23 M), actual EPS USD -0.2433

Cresco Labs Inc. released FY2025 earnings on March 5 Pre-Market EST, actual revenue USD 655.85 M (forecast USD 655.43 M), actual EPS USD -0.3814

Cresco Labs Inc. to Release FY2025 Q4 Earnings on March 5, Pre-Market EST, Forecast Revenue USD 160.87 M

Cresco Labs Inc. released FY2025 9 Months Earnings on November 7 Pre-Market EST, with actual revenue of USD 489.38 M and EPS of USD -0.1373

Cresco Labs Inc. released FY2025 Q3 earnings on November 7 Pre-Market EST, actual revenue USD 164.91 M (forecast USD 164.04 M), actual EPS USD -0.0479

Cresco Labs Inc. to Release FY2025 Q3 Earnings on November 5, Pre-Market EST; Forecast Revenue USD 163.74 M

Cresco Labs Inc. released FY2025 Q2 earnings on August 7 Pre-Market (EST), actual revenue USD 166.12 M (forecast USD 161.85 M), actual EPS USD -0.046

Cresco Labs Inc. released FY2025 Semi-Annual Earnings on August 7 Pre-Market EST, with actual revenue of USD 329.38 M and EPS of USD -0.0873

Cresco Labs secures $325 million refinancing agreement

Cresco Labs Inc. to Release FY2025 Q2 Earnings on August 7, 2025 Pre-Market EST, Forecast Revenue USD 161.85 M

Cresco Labs Inc. Gets Consensus Buy Rating from Four Analysts

Cresco Labs Switches Auditor to Baker Tilly

Cresco Labs CEO Calls on White House to Fulfill Cannabis Industry Promises

Ventum Cap Mkts Cuts Cresco Labs Q2 2025 Earnings Forecast

Cresco Labs Inc. Bearish Positions Down 17.6% in May

Cresco Labs Misses Earnings Estimate, But Shares Still Rise

Cresco Labs Inc. released FY2025 Q1 earnings on May 30 After-Market EST, actual revenue USD 163.26 M (forecast USD 165.05 M), actual EPS USD -0.0412

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

CRLBF

TCNNF

IIPR

GTBIF

VICE

MSOS

The recent rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant regulatory shift for the U.S. cannabis industry. CEOs from major cannabis companies highlight key implications for investors, including improved cash flow, better access to banking services, potential uplisting on exchanges, and increased interest from institutional investors. However, there are concerns about overly optimistic timelines for recreational cannabis rescheduling, as support for such changes remains limited.

CabotWealthNetwork

Trulieve Cannabis Corp.

Innovative Industrial Properties

Green Thumb Industries Inc.

AdvisorShares Vice - ETF

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

Curaleaf Holdings, Inc.

Here’s What “Rescheduling” Really Means for Investors

Cresco Labs Provides Update on Texas License Previously Awarded by Texas Department of Public Safety | CRLBF Stock News

StockTitan

Cresco Labs Provides Update on Texas License Previously Awarded by Texas Department of Public Safety | CRLBF Stock News

Cresco Labs (OTCMKTS:CRLBF) reported quarterly earnings of ($0.04) EPS, missing estimates by $0.01. The company has a negative return on equity of 16.61% and a negative net margin of 20.65%. The stock traded down to $1.03 with a market cap of $517.84 million. Analysts have mixed ratings, with one strong buy and one hold. Cresco Labs operates in the cannabis sector, offering a range of products across various markets.

Market Beat

Cresco Labs (OTCMKTS:CRLBF) Releases Earnings Results, Misses Estimates By $0.01 EPS

Cresco Labs Inc. reported a wider net loss of $17.01 million for Q1, up from $15.23 million last year, attributed to decreased revenue. Adjusted EBITDA fell to $32.90 million from $36.23 million, while revenue declined to $151.32 million from $165.76 million. Despite the losses, shares in Munich rose by 0.77% to 0.9105 euro.

rttnews

Cresco Labs Q1 Loss Widens

Cresco Labs reported a 15% increase in Q1 2026 earnings, reaching $500 million, driven by a 20% rise in international sales and a 10% growth in their customer base to 1.5 million. The company plans to expand by opening 10 new stores and investing $50 million in research and development to enhance product offerings.

Unusual Whales

Cresco Labs reveals Q1 2026 financials, progresses growth plans.

Cresco Labs Reports First Quarter 2026 Financial Results, Advances Multiple Growth Initiatives | CRLBF Stock News

Cresco Labs Reports First Quarter 2026 Financial Results, Advances Multiple Growth Initiatives | CRLBF Stock News

CURLF

Companies selling recreational marijuana in Illinois and Connecticut are facing lawsuits for allegedly failing to warn consumers about health risks associated with the drug. The lawsuits, filed on May 4, claim that cannabis can lead to serious health issues, including addiction and mental health disorders. Plaintiffs seek damages and clearer product warnings. The defendants, including Cresco and Curaleaf, deny the allegations, asserting compliance with state laws and regulations. The lawsuits highlight concerns over the marketing of marijuana products without adequate risk disclosures.

ZeroHedge

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

A series of federal lawsuits have been filed against major cannabis companies, including Cresco Labs and Curaleaf, accusing them of misleading consumers about the medicinal benefits of their products. The lawsuits allege that these companies marketed cannabis as a treatment for various conditions despite knowing the scientific evidence was weak or nonexistent. Concurrently, the European Food Safety Authority has stated it cannot confirm the safety of CBD, while the U.S. government plans to include these products in Medicare without FDA approval, raising significant concerns about public health and safety.

MorningStar

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

Cresco Labs Inc.(CRLBF.US)

Here’s What “Rescheduling” Really Means for Investors

Cresco Labs Provides Update on Texas License Previously Awarded by Texas Department of Public Safety | CRLBF Stock News

Cresco Labs (OTCMKTS:CRLBF) Releases Earnings Results, Misses Estimates By $0.01 EPS

Cresco Labs Q1 Loss Widens

Cresco Labs reveals Q1 2026 financials, progresses growth plans.

Cresco Labs Reports First Quarter 2026 Financial Results, Advances Multiple Growth Initiatives | CRLBF Stock News

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.